Chadé Severin represents private and public companies on a wide range of corporate and securities law matters, including mergers and acquisitions, securities law compliance and other general corporate matters.

Ms. Severin’s representations include:

  • Juno Therapeutics in its $9 billion acquisition by Celgene;

  • Ultragenyx in its successful topping bid for Dimension Therapeutics;
  • Gilead in its $11.9 billion acquisition of Kite Pharma;
  • Merrimack Pharmaceuticals in its asset sale to Ipsen S.A. for up to $1.025 billion;
  • Tobira Therapeutics in its acquisition by Allergan for up to $1.7 billion; and
  • Qlik Technologies in its $3 billion acquisition by Thoma Bravo.



  • J.D., Columbia Law School, 2013
  • B.A., Stanford University, 2007


  • Massachusetts
  • New York

Chadé Severin

Associate, Mergers and Acquisitions